Astellas Fights Teva's Bid To Revoke Its Incontinence Drug IP
Astellas has struck back against litigation filed by a rival pharmaceutical company that is seeking to invalidate its patent for treating urinary problems, arguing that the court should reject the attempt...To view the full article, register now.
Already a subscriber? Click here to view full article